Nutritional issues such as ARFID are highly prevalent among patients with SSc and can lead to poor outcomes and other systemic complications.

Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT study and determine the path forward for efzofitimod in pulmonary sarcoidosis. Phase 2 EFZO-CONNE ...

Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for ...

The PHQ-8 is an important scoring system used to examine depressive symptoms and their severity. Findings from an analysis of the Patient Health Questionnaire (PHQ-8) did not demonstrate substantial ...

University of Virginia School of Medicine researchers have uncovered a possible way to prevent the dangerous hardening of skin and organs in people with systemic scleroderma, a rare autoimmune disease ...

Indero is pleased to announce a strategic collaboration with the World Scleroderma Foundation (WSF) to support WSF SHIELD platform trial, a randomized, double-blind, adaptive platform clinical trial ...

Comorbidity. Just seeing that word makes me cringe. It means having two or more coexisting, and often chronic, health conditions. For many of us in the rare disease community, comorbidity means ...

Background Systemic sclerosis, also known as scleroderma, is a complex, multi-organ disease which causes substantial and progressive fibrosis of the skin and internal organs, including the heart and ...

Scleroderma is a rare autoimmune disease involving an overproduction of the protein collagen. Linear scleroderma usually begins as a streak of hardened, waxy, discolored skin on the forehead, an arm, ...

Scleroderma is an autoimmune condition that causes the skin to become tight and hard. This can change facial appearance, such as the mouth becoming smaller, and affect internal organs. With ...